ASTX660

Description: ASTX660 is an orally bioavailable dual antagonist of cIAP (cellular inhibitor of apoptosis protein) and XIAP (X-linked inhibitor of apoptosis protein). Target: IAP. Smiles: C[C@@H]1CN(CC(=O)N2CC(C)(C)c3nc(CO)c(Cc4ccc(F)cc4)cc23)[C@@H](CN2CCOC[C@H]2C)CN1. References: Tomoko Smyth, et al. Abstract 1287: The dual IAP antagonist, ASTX660, increases the anti-tumor activity of paclitaxel in preclinical models of triple-negative breast cancer in vivo. Cancer Res 2016,76(14 Suppl).